Font J, Coca A, Molina R, Ballesta A, Cardellach F, Ingelmo M, Balague A, Balcells A
Scand J Rheumatol. 1986;15(2):201-5. doi: 10.3109/03009748609102089.
A prospective study of 62 patients with systemic lupus erythematosus (SLE) was performed in order to establish whether serum beta 2m could be a good marker of clinical activity. beta 2m was determined by radio-immunoassay and the values compared with a control group of healthy individuals. The mean value of beta 2m in the control group was 1.48 +/- 0.52 mg/l and 2.87 +/- 2.19 mg/l (p less than 0.001) in the SLE group, 4.53 +/- 2.89 mg/l in the 22 patients with active disease and 2.40 +/- 1.80 mg/l (p less than 0.001) in the 40 patients with inactive disease. High beta 2m values (greater than or equal to 3 mg/l) were observed in 64% of the patients with active SLE, VS. only 12% of the patients with inactive disease (p less than 0.001). Significant differences were also observed when beta 2m of the patients with inactive SLE was compared with the control group (p less than 0.001). The beta 2m with a sensitivity of 64%, a specificity of 87%, and an efficiency of 79% could be a good parameter to detect SLE clinical activity.
对62例系统性红斑狼疮（SLE）患者进行了一项前瞻性研究，以确定血清β2微球蛋白是否可能是临床活动的良好标志物。通过放射免疫测定法测定β2微球蛋白，并将其值与健康个体的对照组进行比较。对照组中β2微球蛋白的平均值为1.48±0.52mg/L，SLE组为2.87±2.19mg/L（p<0.001），22例活动期疾病患者为4.53±2.89mg/L，40例非活动期疾病患者为2.40±1.80mg/L（p<0.001）。64%的活动期SLE患者观察到高β2微球蛋白值（大于或等于3mg/L），相比之下，非活动期疾病患者仅为12%（p<0.001）。将非活动期SLE患者的β2微球蛋白与对照组比较时也观察到显著差异（p<0.001）。β2微球蛋白的敏感性为64%，特异性为87%，有效性为79%可能是检测SLE临床活动的良好参数。
